Review Article
Th17 Response and Inflammatory Autoimmune Diseases
Table 2
Clinical aspect of therapies targeting the IL-17 pathway.
| Disease | Sera | Biopsies | Cell type | SNPs or mutations | Therapy targeting Th17 pathway | Reference |
| Multiple sclerosis | | IL-17A mRNA is detected in cerebrospinal fluid mononuclear cells | Myelin-reactive Th17+ cells are enriched and express high IL-22 and IFNγ | | Anti-p40 subunit of IL-12/23 (ustekinumab) (no effect) | [73–75] | Rheumatoid arthritis | IL-17 | IL-17 | Synoviocytes express IL-1b and IL-6 in response to IL-17 | | Anti-IL-6R (Tocilizumab); IL-1 receptor antagonist (anakinra); anti-IL17 (LY2439821, others) | [69, 72, 76–78] | Systemic lupus erythematosus | IL-17 | IL-17 | | | | [18, 70, 71] | Psoriasis | | IL-17A, IL-22, and IL-23 | CD8+ T cells secreting IL-17 and IL-22 (Tc17 and Tc22, respectively) | IL-23 pathway | Anti-p40 subunit of IL-12 and IL-23 (ustekinumab) | [79–82] | Inflammatory Bowel disease | | | | IL-23 pathway | | [83] | Crohn’s disease | | IL-17+ (RORγT+ IL-23R+ and CCR6+ cells) | Th17 (CD161+CD4+ T cells) | | Anti-IL-6R (Tocilizumab); anti-p40 subunit of IL-12/23 (ustekinumab) | [76, 84–86] |
|
|